1971
Drs. Prati, Hull and Associates was founded in June 1971. At the time, there were two physicians and less than 10 administrative support members. The subspecialty of nephrology was new.
Dr. Alan R. Hull became elected as the first president of Drs. Prati, Hull and Associates.
1975
Dallas Kidney Disease Center opened under by Drs. Prati, Hull and Associates. It was the second dialysis center to open in Dallas and, at the time, it was the largest dialysis center in the world, with 53 dialysis stations.
Drs. Hull and White along with Paul Peters, Sr., established Southwest Organ Bank, a nonprofit organ recovery organization. With support from The University of Texas Southwestern Medical Center, the organization increased the availability of kidneys for transplant. Dr. Martin White served as the organization’s founding president until 2002. (Source: BUMC Group Practice Article – F. David Winter, Jr., MD)
1976
Drs. Prati, Hull and Associates changed its name to Dallas Nephrology Associates.
1981
Dallas Nephrology Associates’ physicians, led by Dr. Pedro Vergne-Marini, assisted in the developing the Methodist Medical Center transplant program. The program performed their first kidney transplant in 1981.
Dallas Nephrology Associates opens Dallas Transplant Institute. This Institute provides medical care for post-kidney and kidney/pancreas transplant patients and coordinates the medical evaluation for patients with CKD who are pursuing kidney transplantation.
Dr. Thomas Parker, III, helped to lead the National Cooperative Dialysis Study (NCDS), the first randomized controlled trial to examine the effect of dialysis dose on patient outcomes. Prior to this study, standardized targets for dialysis treatment were not well established. The NCDS provided important evidence supporting the use of small-solute clearance to help quantify dialysis dose.
1985
Dr. Martin G. White was elected as president of Dallas Nephrology Associates.
Dallas Nephrology Associates assisted in the development of the Baylor Transplant Program.
1989
Dallas Nephrology Associates began a multicenter study to assess the impact of increasing the delivered quantity of dialysis on mortality in subsequent years. Dialysis dose was measured by urea kinetic modeling. Kt/V, reflecting the fractional volume of body water clearance of urea during a dialysis treatment.
1992
By 1992, Dallas Nephrology Associates and National Medical Care had standardized mortality ratios of 0.77 and 0.74, respectively, compared with the US dialysis population, indicating almost 30% fewer observed deaths than expected resulted from the increase in Kt/V.
1996
Dr. Pedro Vergne-Marini was elected as President of Dallas Nephrology Associates. Dr. Vergne was instrumental in creating new relationships with many dialysis partners.
1999
Medical City Dallas Hospital expanded their transplant program to include kidney transplants. Our physicians included Medical Directors of the transplant program.
2000
Dr. Ruben Velez was elected as President of Dallas Nephrology Associates. Dr. Velez served as President for 16 years. Under his leadership, DNA grew tremendously throughout the metroplex.
2003
Baylor All Saints Medical Center in Fort Worth opened a transplant program with Dallas Nephrology Associates physicians providing both pre-transplant evaluation and post-transplant care.
Dr. Thomas Parker chaired the CKD Initiative workshop held by the Chronic Kidney Disease Initiative (CKDI) in Washington, DC. The CKDI was implemented at the request of the Council of American Kidney Societies to formulate a plan of action to solve many of the perceived problems associated with identifying, caring for, and attaining the best outcomes for patients with chronic kidney disease.
2006
DNA Plano Vascular Center was opened. DNA Plano Vascular Center provides advanced, effective vascular-access management care to patients with dialysis access.
2007
The 80th Texas Legislature passed House Bill 1373 in 2007, establishing the Chronic Kidney Disease Task Force (Task Force).
This task force was directed to develop a plan to educate health care professionals about the advantages and methods of early screening, diagnosis, and the treatment of CKD and its complications including early renal replacement therapy.
2008
DNA Dallas Vascular Center was acquired from U.S. Vascular Access Services. The DNA Dallas Vascular Center provides advanced, effective vascular-access management care to patients with dialysis access. Our medical teams at both of our Vascular Centers include both Interventional Radiologists and Interventional Nephrologist, as well as surgical support staff.
2015
Renal Disease Research Institute was formed as an affiliate of Dallas Nephrology Associates. Its mission is to offer individuals the opportunity to participate in clinical research by managing scientifically feasible and ethical clinical trials.
2016
Dr. Alexander Liang was elected as President of Dallas Nephrology Associates.
DNA was one of thirteen original pioneer members of ESCO, an ESRD specialty ACO.
2019
Dr. Steven Hays becomes President of the Texas Chapter of the American College of Physicians.
Dallas Nephrology Associates’ Vascular Center is the first in Texas to create non-surgical dialysis fistulas using two FDA-approved systems.
2020
Dr. Roberto Collazo-Maldonado of Dallas Nephrology Associates was appointed to Chronic Kidney Disease Task Force by Governor Greg Abbott.
Texas House Bill 1225, named The Glenda Dawson Act, had re-established the Chronic Kidney Disease Task Force to coordinate the implementation of the state’s plan to increase CKD prevention, early screening, diagnosis, and management.
Dr. Neghae Mawla, an interventional nephrologist, also completed the 100th EndoAVF procedure at the DNA Vascular Center in Plano. This minimally invasive procedure offered a new approach to creating fistulas for patients preparing for hemodialysis.
Dr. Archana Rao was elected to the Dallas County Medical Society Board of Directors.
2021
For more than 50 years, Dallas Nephrology Associates has cared for patients with kidney disease, hypertension, transplants, and complex electrolyte disorders. Although kidney care has changed significantly over the decades, our commitment remains the same: providing patients with expert, personalized care using advanced treatments and technologies.
That commitment is supported by our physicians, advanced practice providers, and hundreds of staff members who care for patients with compassion and dedication.